Alpharma — Merger or Acquisition (September 2008)
23 slides from Alpharma's merger presentation, Sep 11, 2008
Slide 1: King to Commence Cash Tender Offer for Alpharma at $37 Per Share
FOR IMMEDIATE RELEASE KING TO COMMENCE CASH TENDER OFFER FOR ALPHARMA AT $37 PER SHARE BRISTOL, TN., September 11, 2008 — King Pharmaceuticals, Inc. (NYSE: KG) today announced that it intends to commence a cash tender offer to acquire all of the outstanding shares of Class A Common Stock of Alpharma
Slide 2: King's Offer to Acquire Alpharma Inc. Creates a Leading Specialty Pharma Company
(c) King Pharmaceuticals, 2008. No materials contained in this presentation shall be reproduced or redistributed in any form. King's Offer to Acquire Alpharma Inc. Creates a Leading Specialty Pharma Company September 2008
Slide 3: Forward-looking Statements
Forward-looking Statements This document contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). King Pharmaceuticals, Inc. ("King") disclaims any intent or obligation to update these forward-looking statements, and claims the protection
Slide 4: Presentation Outline
Presentation Outline 1. Transaction Summary and Rationale 2. King's Strategy 3. King-Alpharma Combination
Slide 5: Transaction Summary and Rationale
1. Transaction Summary and Rationale
Slide 6: Transaction Update
Transaction Update King commenced tender offer to acquire Alpharma for $37 per share1 Fully committed financing Filed for HSR approval and confident that regulatory requirements will be met in a timely manner Transaction expected to close by the end of 2008
Slide 7: Enhanced Offer Delivers Superior Value to Alpharma Stockholders
Enhanced Offer Delivers Superior Value to Alpharma Stockholders Tender offer price of $37 per share in cash provides: 67% premium to Alpharma's closing price on August 4, 2008 (the date of King's initial private written proposal) 54% premium to Alpharma's closing price on August 21, 2008 (the last t
Slide 8: Transaction Creates Stronger Platform for King's Long-Term Growth
Transaction Creates Stronger Platform for King's Long-Term Growth Creates a leading specialty pharmaceutical company with greater scale and capabilities Expanded portfolio of pain management products - including multiple platform technologies designed to deliver new innovative products Four potentia
Slide 9: King's Strategy
2. King's Strategy
Slide 10: King Today
King Today A developer and acquirer of novel branded prescription pharmaceutical products that have significant market potential Focused in three specialty driven markets Neuroscience Hospital Acute Care A leader and partner of choice in bringing innovative, clinically-differentiated medicines and t
Slide 11: King's Current Portfolio
EpiPen(r) EpiPen(r) Canada Bio-defense products T-62 Oradur(tm) Technology Platform (PTIE)3 Aversion(r) Technology Platform (Acura)4 Thrombi-Gel(r) (surgical indication) Thrombi-Paste(tm) CorVue(r) Remoxy(r) Acurox(tm) Tablets Thrombin-JMI(r) Thrombi-Pad(tm) Thrombi-Gel(r) Epistaxis Kit Skelaxin(r)
Slide 12: Fully-Aligned 690 Person Sales Force
Sales Force: 415 Avinza(r) Skelaxin(r) Neuroscience/Pain Specialists Sales Force: 155 Avinza(r) Skelaxin(r) Hospital Specialists Sales Force: 120 Thrombin-JMI(r) Thrombi-Gel(r) Thrombi-Pad(tm) Epistaxis Kit Fully-Aligned 690 Person Sales Force Primary Care EXPERIENCED MANAGED CARE TEAM
Slide 13: Neuroscience Portfolio Positions King as a Leader in Pain Management
DEVELOPMENT MARKETED Remoxy(r) Acurox(tm) Tablets Avinza(r) Neuroscience Portfolio Immediate and Extended Release Abuse-deterrent Platforms Position King as a Leader in Pain Management Skelaxin(r) T-62 Oradur(tm) Technology Platform (PTIE) Aversion(r) Technology Platform (Acura)
Slide 14: Focus on Pain: Patient Landscape
Focus on Pain: Patient Landscape More than 75 million Americans suffer from pain - more than the number of people with diabetes, heart disease and cancer combined5 An estimated 50 million Americans live with chronic pain, a serious and complex medical condition6 Commonly caused by arthritis, lower b
Slide 15: Issues in the Treatment of Pain - a Complex Societal Issue
Issues in the Treatment of Pain - a Complex Societal Issue Chronic pain often remains undertreated Despite the availability of effective prescription opioid pain medications Misuse, abuse and diversion of opioid products has significantly influenced physicians' willingness to prescribe them In fact,
Slide 16: Prescription Opioid Abuse - A Significant and Growing Problem
Prescription Opioid Abuse - A Significant and Growing Problem 5.2 million Americans used prescription pain relievers for non-medical use in 200610 Each day approximately 2,500 teens try abusing prescription painkillers for the first time11 4.3% of high school seniors abused long-acting oxycodone 9.7
Slide 17: Opioid Segments and Market Opportunity
Immediate Release Opioid Segment $2 Billion15 170 Million TRx's Current Marketplace Vicodin Tylenol w Codeine Percocet Dialaudid Opana IR Various Generics Extended Release Opioid Segment $4 Billion15 19 Million TRx's Current Marketplace OxyContin Duragesic Avinza Kadian MS-Contin Opana ER Various Ge
Slide 18: An Integrated Approach to Growth
An Integrated Approach to Growth Specialty Driven Markets Corporate Growth Strategy Organic Growth Maximize current product potential Develop pipeline products Enhance capabilities and maximize efficiency Leverage core capabilities and assets Develop partnerships for promising products and technolog
Slide 19: King-Alpharma Combination
3. King-Alpharma Combination
Slide 20: Combined Company Creates A Diversified Pain Portfolio
Combined Company Creates A Diversified Pain Portfolio Combined Skelaxin(r) Avinza(r) Remoxy(r) (NDA Filed) Acurox(tm) (Phase III) Kadian(r) Flector(r) Patch Embeda (NDA Filed) Ketoprofen Gel (Phase III) T-62 (Phase II) EpiPen(r) Bio-defense products Vanquix (Phase III) King Skelaxin(r) Avinza(r) Rem
Slide 21: Combined R&D Pipeline
Combined R&D Pipeline PLATFORM TECHNOLOGIES Phase III Ongoing Topical non-steroidal anti-inflammatory ("NSAID") Ketoprofen in TRANSFERSOME(r) Gel NDA Filed/Priority Review Long-acting morphine tablets Embeda(tm) abuse-deterrent Acurox(tm) and other short-acting abuse-resistant/deterrent opioids Aver
Slide 22: Compelling Transaction
Compelling Transaction Value creation for both King and Alpharma stockholders Strong strategic fit Opportunity to increase scale and depth in neuroscience/pain Excellent platform for sustainable, long-term growth Proposed combination could receive all necessary regulatory approvals and be completed
Slide 23: End Notes
End Notes See King's Schedule TO on file with the SEC for the full terms and conditions of the offer Principally from savings in general and administrative expenses, research and development expenses and savings to be achieved by avoiding the expense of hiring additional sales representatives for th